Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Addex Therapeutics Ltd (ADXN.SW)

Swiss - Swiss Delayed Price. Currency in CHF
0.2050+0.0200 (+10.81%)
At close: 05:30PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.1850
Open0.1850
Bid0.2055 x 0
Ask0.1930 x 0
Day's Range0.1850 - 0.2050
52 Week Range0.1006 - 0.9400
Volume277,019
Avg. Volume194,458
Market Cap23.646M
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)-0.5260
Earnings DateMay 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ADXN.SW

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Addex Provides Corporate Update and Financial Guidance

      Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 19, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today provided a corporate update, including a review of its pipeline and financial guidance. “We ended 2022 with CHF7.0 million of cash and expect to be able to finance our operations until Q3 2023. We continue to focus on entering into collaborative arra

    • GlobeNewswire

      Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration

      Addex to receive USD 1 million in additional research fundingCollaboration continues to advance through drug candidate selection phase Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 8, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the research term of its collaboration agreement with Indivior PLC (LON: INDV) for the discovery of novel o

    • GlobeNewswire

      Addex Reports Q3 2022 Financial Results and Provides Corporate Update

      CHF10.4M ($10.4M) of cash and cash equivalents at September 30, 2022Janssen led ADX71149 Phase 2 study in epilepsy on track to complete part 1 in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its Q3 financial results for the period ended September 30, 2022 and provided a corporate upd

    Advertisement
    Advertisement